Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- OM:CEVI
CellaVision First Quarter 2024 Earnings: EPS: kr1.26 (vs kr0.81 in 1Q 2023)
CellaVision (STO:CEVI) First Quarter 2024 Results
Key Financial Results
- Revenue: kr170.1m (up 22% from 1Q 2023).
- Net income: kr30.1m (up 57% from 1Q 2023).
- Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue.
- EPS: kr1.26 (up from kr0.81 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CellaVision Earnings Insights
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 1.8% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on CellaVision's balance sheet.
Valuation is complex, but we're helping make it simple.
Find out whether CellaVision is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CEVI
CellaVision
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally.
High growth potential with excellent balance sheet.